CU20130107A7 - IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS - Google Patents
IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOSInfo
- Publication number
- CU20130107A7 CU20130107A7 CU2013000107A CU20130107A CU20130107A7 CU 20130107 A7 CU20130107 A7 CU 20130107A7 CU 2013000107 A CU2013000107 A CU 2013000107A CU 20130107 A CU20130107 A CU 20130107A CU 20130107 A7 CU20130107 A7 CU 20130107A7
- Authority
- CU
- Cuba
- Prior art keywords
- treatment
- triazins
- imidazo
- neurological disorders
- compounds
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de Fórmula y a sales de los mismos farmacéuticamente aceptables, a procedimientos para la preparación de, a intermedios usados en la preparación de, y composiciones que contienen dichos compuestos y a los usos de dichos compuestos como un porcedimiento para el tratamiento, de una enfermedad o afección seleccionada del grupo que consiste en trastornos del sistema nervioso central, trastornos cognitivos, esquizofrenia, demencia y otros trastornos, en un mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445617P | 2011-02-23 | 2011-02-23 | |
| PCT/IB2012/050589 WO2012114222A1 (en) | 2011-02-23 | 2012-02-09 | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20130107A7 true CU20130107A7 (es) | 2013-09-27 |
Family
ID=45755439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2013000107A CU20130107A7 (es) | 2011-02-23 | 2013-07-30 | IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8598155B2 (es) |
| EP (1) | EP2681218A1 (es) |
| JP (1) | JP5543039B2 (es) |
| KR (1) | KR101548443B1 (es) |
| CN (1) | CN103391941A (es) |
| AP (1) | AP2013007070A0 (es) |
| AR (1) | AR085304A1 (es) |
| AU (1) | AU2012221828C1 (es) |
| BR (1) | BR112013021366A2 (es) |
| CA (1) | CA2825699A1 (es) |
| CL (1) | CL2013002125A1 (es) |
| CO (1) | CO6751271A2 (es) |
| CR (1) | CR20130371A (es) |
| CU (1) | CU20130107A7 (es) |
| DO (1) | DOP2013000194A (es) |
| EA (1) | EA022586B1 (es) |
| EC (1) | ECSP13012892A (es) |
| GT (1) | GT201300206A (es) |
| IL (1) | IL227716A0 (es) |
| MA (1) | MA34922B1 (es) |
| MX (1) | MX2013009684A (es) |
| NI (1) | NI201300071A (es) |
| PE (1) | PE20140236A1 (es) |
| PH (1) | PH12013501556A1 (es) |
| SG (1) | SG192576A1 (es) |
| TN (1) | TN2013000349A1 (es) |
| TW (1) | TWI469983B (es) |
| UA (1) | UA106692C2 (es) |
| UY (1) | UY33916A (es) |
| WO (1) | WO2012114222A1 (es) |
| ZA (1) | ZA201306348B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5543039B2 (ja) * | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| MD20150103A2 (ro) * | 2013-05-02 | 2016-02-29 | Pfizer Inc. | Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 |
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 製剤および医薬組成物 |
| EP3134413B1 (en) * | 2014-04-23 | 2019-09-11 | Dart NeuroScience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學(開曼)有限責任公司 | 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物 |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN104525240A (zh) * | 2014-12-10 | 2015-04-22 | 河北工业大学 | 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法 |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| TWI713497B (zh) * | 2015-02-26 | 2020-12-21 | 南韓商愛思開生物製藥股份有限公司 | 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物 |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3291817B1 (en) | 2015-05-05 | 2019-10-02 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| CA3001768C (en) * | 2015-11-02 | 2022-12-13 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
| KR20190070972A (ko) | 2016-11-02 | 2019-06-21 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체 |
| WO2018083101A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| WO2018083103A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| TW201837026A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物(二) |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| US11419874B2 (en) | 2017-11-23 | 2022-08-23 | Oslo University Hospital Hf | Treatment of tachycardia |
| CN108640923A (zh) * | 2018-07-09 | 2018-10-12 | 湖南天地恒制药有限公司 | 一种托法替布关键中间体的制备方法 |
| US12180210B2 (en) * | 2018-10-23 | 2024-12-31 | Intra-Cellular Therapies, Inc. | Compounds |
| US11492362B1 (en) | 2022-02-17 | 2022-11-08 | King Abdulaziz University | Pyridine derivatives for the treatment of hyperproliferative diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993012113A1 (en) * | 1991-12-17 | 1993-06-24 | The Upjohn Company | 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY |
| YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
| DE10130167A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| DE10230605A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| DE10230604A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| WO2005041957A1 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
| MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP5130053B2 (ja) * | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| CA2630271C (en) | 2005-11-17 | 2014-04-08 | Osi Pharmaceuticals, Inc. | Fused bicyclic mtor inhibitors |
| EP1981890A2 (en) | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| WO2007106503A2 (en) | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| WO2009008992A2 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
| US7683575B2 (en) | 2007-07-18 | 2010-03-23 | Tesla Motors, Inc. | Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack |
| MX2010010300A (es) | 2008-03-19 | 2010-10-26 | Osi Pharm Inc | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. |
| ES2396613T3 (es) | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| BR112012000494A2 (pt) | 2009-07-09 | 2015-09-15 | Osi Pharmaceuticals Llc | processo para 3-amino-5-oxo-4,5-di-hidro-[1,2,4]triazinas substituídas |
| MX2012008898A (es) | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| JP5543039B2 (ja) * | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン |
-
2012
- 2012-02-09 JP JP2013554958A patent/JP5543039B2/ja not_active Expired - Fee Related
- 2012-02-09 EA EA201390971A patent/EA022586B1/ru not_active IP Right Cessation
- 2012-02-09 UA UAA201309471A patent/UA106692C2/uk unknown
- 2012-02-09 KR KR1020137024689A patent/KR101548443B1/ko not_active Expired - Fee Related
- 2012-02-09 SG SG2013055298A patent/SG192576A1/en unknown
- 2012-02-09 AU AU2012221828A patent/AU2012221828C1/en not_active Ceased
- 2012-02-09 PE PE2013001976A patent/PE20140236A1/es not_active Application Discontinuation
- 2012-02-09 MX MX2013009684A patent/MX2013009684A/es not_active Application Discontinuation
- 2012-02-09 PH PH1/2013/501556A patent/PH12013501556A1/en unknown
- 2012-02-09 CN CN2012800101209A patent/CN103391941A/zh active Pending
- 2012-02-09 CA CA2825699A patent/CA2825699A1/en not_active Abandoned
- 2012-02-09 BR BR112013021366A patent/BR112013021366A2/pt not_active IP Right Cessation
- 2012-02-09 WO PCT/IB2012/050589 patent/WO2012114222A1/en not_active Ceased
- 2012-02-09 EP EP12705448.4A patent/EP2681218A1/en not_active Withdrawn
- 2012-02-09 AP AP2013007070A patent/AP2013007070A0/xx unknown
- 2012-02-20 US US13/400,172 patent/US8598155B2/en active Active
- 2012-02-20 TW TW101105525A patent/TWI469983B/zh not_active IP Right Cessation
- 2012-02-22 AR ARP120100575A patent/AR085304A1/es unknown
- 2012-02-22 UY UY0001033916A patent/UY33916A/es not_active Application Discontinuation
-
2013
- 2013-07-24 CL CL2013002125A patent/CL2013002125A1/es unknown
- 2013-07-29 IL IL227716A patent/IL227716A0/en unknown
- 2013-07-30 CU CU2013000107A patent/CU20130107A7/es unknown
- 2013-07-31 CR CR20130371A patent/CR20130371A/es unknown
- 2013-08-19 TN TNP2013000349A patent/TN2013000349A1/fr unknown
- 2013-08-22 ZA ZA2013/06348A patent/ZA201306348B/en unknown
- 2013-08-22 CO CO13199523A patent/CO6751271A2/es unknown
- 2013-08-22 GT GT201300206A patent/GT201300206A/es unknown
- 2013-08-22 NI NI201300071A patent/NI201300071A/es unknown
- 2013-08-23 DO DO2013000194A patent/DOP2013000194A/es unknown
- 2013-08-23 MA MA36201A patent/MA34922B1/fr unknown
- 2013-09-23 EC ECSP13012892 patent/ECSP13012892A/es unknown
- 2013-11-01 US US14/069,640 patent/US9200000B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33916A (es) | ?IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS? | |
| PE20150706A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| CL2019001626A1 (es) | Inhibidores de pequeñas moléculas de la familia jak de quinasas. | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| AR123407A1 (es) | Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4,5:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol | |
| MX2012004157A (es) | 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc. | |
| CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
| CL2009000975A1 (es) | Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer. | |
| SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
| MX2015011618A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso. | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| PE20150669A1 (es) | Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1 | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| NI201700055A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| CO2018005163A2 (es) | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| CO6592112A2 (es) | Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn | |
| BR112014012031A2 (pt) | derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1 | |
| UY34281A (es) | "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina |